Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) treatment results in high grade bladder tumors.

During 1996 and 1999, we applied MVAC in 27 patients whose final stage bladder tumor depends on pathological and radiological bases at urological department. 15.4 % had complete response, 34.6 % had partial clinical response, 34.8 % hadn’t any clinical response and 19.7% had progression. One of the patient died due to a wide spreed tumor metastasis and neutropenic sepsis during the treatment. The most common side-effects were nausea- vomiting, transient renal failure, leucopenia, and trombocytopenia. M-VAC therapy showed it’s beneficial effect by decreasing the stage so providing TUR possibility and other alternative surgical procedurs.